These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31695203)

  • 41. Estimating the full public health value of vaccination.
    Gessner BD; Kaslow D; Louis J; Neuzil K; O'Brien KL; Picot V; Pang T; Parashar UD; Saadatian-Elahi M; Nelson CB
    Vaccine; 2017 Nov; 35(46):6255-6263. PubMed ID: 28986035
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
    Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L
    Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What can be done to make vaccines more trendy?
    Andre FE
    Expert Rev Vaccines; 2005 Feb; 4(1):23-5. PubMed ID: 15757470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gaps in vaccine financing for underinsured children in the United States.
    Lee GM; Santoli JM; Hannan C; Messonnier ML; Sabin JE; Rusinak D; Gay C; Lett SM; Lieu TA
    JAMA; 2007 Aug; 298(6):638-43. PubMed ID: 17684186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Perspectives on expanding the evidence base to inform vaccine introduction: Program costing and cost-effectiveness analyses.
    Andrus JK; Walker DG
    Vaccine; 2015 May; 33 Suppl 1():A2-3. PubMed ID: 25919161
    [No Abstract]   [Full Text] [Related]  

  • 46. The societal value of universal childhood vaccination.
    Chabot I; Goetghebeur MM; Grégoire JP
    Vaccine; 2004 May; 22(15-16):1992-2005. PubMed ID: 15121312
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The U.S. vaccine and immunization enterprise: Working to sustain and foster vaccine innovation.
    Shen AK
    Hum Vaccin; 2009 Oct; 5(10):649-53. PubMed ID: 19713758
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modern vaccines. Progress towards vaccines we need and do not have.
    Robbins A
    Lancet; 1990 Jun; 335(8703):1436-8. PubMed ID: 1972216
    [No Abstract]   [Full Text] [Related]  

  • 49. Partnering for Vaccine Emerging Markets--Berlin, June 10-11, 2013: balancing vaccine quality, capacity, and cost-of-goods in emerging markets.
    Onraedt A
    Hum Vaccin Immunother; 2013 Sep; 9(9):2022-4. PubMed ID: 23966097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaccines for the world: major challenges for the future.
    Lambert PH
    Southeast Asian J Trop Med Public Health; 1997; 28 Suppl 2():122-6. PubMed ID: 9561647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Academic science and the business of vaccines.
    Johnston RE
    Arch Virol Suppl; 2005; (19):203-6. PubMed ID: 16355874
    [No Abstract]   [Full Text] [Related]  

  • 52. Plea to restore public funding for vaccine development.
    Puliyel JM
    Lancet; 2004 Feb; 363(9409):659. PubMed ID: 14987898
    [No Abstract]   [Full Text] [Related]  

  • 53. New vaccines.
    Stanley PJ; Ellis CJ
    Br J Hosp Med; 1989 Apr; 41(4):364-7. PubMed ID: 2655801
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Foreword.
    Etienne CF
    Vaccine; 2015 May; 33 Suppl 1():A1. PubMed ID: 25919148
    [No Abstract]   [Full Text] [Related]  

  • 55. European strategy for vaccine development against infectious diseases.
    Matthiessen L; Lång H; Klimathianaki M; Hanrahan F; Kerstiëns B; Martini A; Draghia-Akli R
    Vaccine; 2017 Jan; 35 Suppl 1():A20-A23. PubMed ID: 28017443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States.
    Shen AK; Rodewald LE; Birkhead GS
    Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaccination lags behind in middle-income countries.
    Berkley S
    Nature; 2019 May; 569(7756):309. PubMed ID: 31089234
    [No Abstract]   [Full Text] [Related]  

  • 58. National immunization programmes.
    Cherian T; Mantel C
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Jan; 63(1):16-24. PubMed ID: 31792552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sustainable introduction of affordable new vaccines: the targeting strategy.
    Batson A
    Vaccine; 1998 Nov; 16 Suppl():S93-8. PubMed ID: 9915047
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 11th Annual Conference on Vaccine Research.
    O'Brien J
    Expert Rev Vaccines; 2008 Aug; 7(6):721-3. PubMed ID: 18665770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.